Cargando…
Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance to gemcitabine, the first line chemotherapeutic approach. Thus, there is a strong need for novel therapies, targeting more directly the molec...
Autores principales: | Calabretta, Sara, Bielli, Pamela, Passacantilli, Ilaria, Pilozzi, Emanuela, Fendrich, Volker, Capurso, Gabriele, Delle Fave, Gianfranco, Sette, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650269/ https://www.ncbi.nlm.nih.gov/pubmed/26234680 http://dx.doi.org/10.1038/onc.2015.270 |
Ejemplares similares
-
Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells
por: Passacantilli, Ilaria, et al.
Publicado: (2017) -
Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
por: Passacantilli, Ilaria, et al.
Publicado: (2014) -
Regulation of BCL-X splicing reveals a role for the polypyrimidine tract binding protein (PTBP1/hnRNP I) in alternative 5′ splice site selection
por: Bielli, Pamela, et al.
Publicado: (2014) -
Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems
por: Capurso, Gabriele, et al.
Publicado: (2012) -
Tumor suppressor SMAR1 regulates PKM alternative splicing by HDAC6-mediated deacetylation of PTBP1
por: Choksi, Arpankumar, et al.
Publicado: (2021)